A Phase I Clinical Trial of Vorinostat in Combination With Vinorelbine in Patients With Advanced Cancer
Latest Information Update: 10 May 2022
Price :
$35 *
At a glance
- Drugs Vinorelbine (Primary) ; Vorinostat (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 19 May 2010 Status changed from recruiting to discontinued as reported by clinicalTrials.gov record.
- 19 May 2010 Status changed from recruiting to discontinued as reported by clinicalTrials.gov record.
- 17 Mar 2009 Status changed from not yet recruiting to recruiting, as reported by clinicalTrials.gov record.